Bamlanivimab/ Etesevimab (Eli Lilly)

Markiert sind besonders wichtige Quellen.

• Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12

  investor.lilly.com, hinzugefügt am 06.12.2021, wichtige Quelle

• EMA stoppt Prüfung von Coronamedikament

  aerzteblatt.de, hinzugefügt am 04.11.2021, wichtige Quelle

• Bamlanivimab for Prevention of COVID-19

  jamanetwork.com, hinzugefügt am 06.06.2021, wichtige Quelle

• Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

  jamanetwork.com, hinzugefügt am 06.06.2021, wichtige Quelle

• Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

  investor.lilly.com, hinzugefügt am 10.03.2021, wichtige Quelle

• Omicron sublineage BQ.1.1 resistance to monoclonal antibodies

  thelancet.com, hinzugefügt am 19.11.2022

• BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

  nature.com, hinzugefügt am 24.06.2022

• SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasion

  biorxiv.org, hinzugefügt am 30.05.2022

• Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies

  biorxiv.org, hinzugefügt am 10.05.2022

• New Members Of The Omicron Family Of Viruses: BA.2.12.1, BA.4, And BA.5

  forbes.com, hinzugefügt am 26.04.2022

• Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual

  medrxiv.org, hinzugefügt am 26.04.2022

• Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

  nejm.org, hinzugefügt am 11.03.2022

• Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

  nejm.org, hinzugefügt am 17.02.2022

• Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

  biorxiv.org, hinzugefügt am 10.01.2022

• Reported in vitro Therapeutic Activity

  opendata.ncats.nih.gov, hinzugefügt am 18.12.2021

• An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies

  biorxiv.org, hinzugefügt am 18.12.2021

• The Omicron variant is highly resistant against antibody-mediated 2 neutralization – implications for control of the COVID-19 pandemic

  biorxiv.org, hinzugefügt am 17.12.2021

• Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

  biorxiv.org, hinzugefügt am 17.12.2021

• Lilly pulls COVID-19 treatment from EU review while U.S. stocks up

  reuters.com, hinzugefügt am 09.11.2021

• Monoclonal antibodies can prevent COVID-19—but successful vaccines complicate their future

  science.org, hinzugefügt am 03.11.2021

• B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination

  cell.com, hinzugefügt am 22.10.2021

• Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19

  investor.lilly.com, hinzugefügt am 19.09.2021

• Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

  jci.org, hinzugefügt am 15.09.2021

• Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

  thelancet.com, hinzugefügt am 20.07.2021

• Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

  nejm.org, hinzugefügt am 17.07.2021

• Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

  nature.com, hinzugefügt am 13.07.2021

• SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination

  cell.com, hinzugefügt am 30.06.2021

• EXCLUSIVE U.S. opens criminal probe into alleged lapses at Eli Lilly plant

  reuters.com, hinzugefügt am 28.05.2021

• Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection

  academic.oup.com, hinzugefügt am 20.05.2021

• SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination

  biorxiv.org, hinzugefügt am 06.05.2021

• Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab Alternative monoclonal antibody therapies authorized to treat patients with COVID-19 remain available

  fda.gov, hinzugefügt am 17.04.2021

• Pharma With variants spreading, Eli Lilly cuts solo COVID-19 antibody out of its U.S. supply deal

  fiercepharma.com, hinzugefügt am 14.04.2021

• The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates

  stm.sciencemag.org, hinzugefügt am 09.04.2021

• Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

  cell.com, hinzugefügt am 06.04.2021

• US government stops distribution of Eli Lilly Covid-19 antibody treatment due to spread of coronavirus variants

  edition.cnn.com, hinzugefügt am 26.03.2021

• U.S. limits supply of Eli Lilly’s Covid-19 antibody therapy in California, Arizona and Nevada

  cnbc.com, hinzugefügt am 14.03.2021

• Europäische Arzneimittelagentur prüft Antikörpertherapie gegen COVID-19

  aerzteblatt.de, hinzugefügt am 13.03.2021

• Europe begins rolling review of Eli Lilly's antibodies for Covid-19

  theedgemarkets.com, hinzugefügt am 11.03.2021

• Eli Lilly's combo therapy for COVID-19 cuts serious illness and death in large study

  reuters.com, hinzugefügt am 10.03.2021

• BAMLANIVIMAB GEGEN COVID-19?

  arznei-telegramm.de, hinzugefügt am 24.02.2021

• Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19

  investor.lilly.com, hinzugefügt am 10.02.2021

• Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

  fda.gov, hinzugefügt am 10.02.2021

• https://www.fda.gov/media/143603/download

  fda.gov, hinzugefügt am 07.02.2021

• SARS-CoV-2: Forscher finden weitere Mutationen für ein Immunescape

  aerzteblatt.de, hinzugefügt am 27.01.2021

• New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent

  investor.lilly.com, hinzugefügt am 26.01.2021

• Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

  science.sciencemag.org, hinzugefügt am 26.01.2021

• Monoclonal antibodies can prevent COVID-19—but successful vaccines complicate their future

  sciencemag.org, hinzugefügt am 23.01.2021

• SARS-CoV-2: Antikörper erzielt primärpräventive Wirkung bei Bewohnern und Mitarbeitern von Pflegeheimen

  aerzteblatt.de, hinzugefügt am 23.01.2021

• Monoclonal Antibody Combo Treatment Reduces Viral Load in Mild-to-Moderate COVID

  medscape.com, hinzugefügt am 22.01.2021

• Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

  jamanetwork.com, hinzugefügt am 22.01.2021

• Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents

  investor.lilly.com, hinzugefügt am 21.01.2021

• Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of Bamlanivimab for Coronavirus Disease 2019 (COVID-19)

  fda.gov, hinzugefügt am 11.01.2021

• An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19

  jamanetwork.com, hinzugefügt am 07.01.2021

• Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs

  investor.lilly.com, hinzugefügt am 07.01.2021

• Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial

  lilly.com, hinzugefügt am 07.01.2021

• SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

  nejm.org, hinzugefügt am 07.01.2021

• A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

  nejm.org, hinzugefügt am 07.01.2021

Keine Quelle enthält diesen Text.